Nu Skin Enterprises Inc. (NUS)

$12.7

+0.34

(+2.75%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Nu Skin Enterprises Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 500.25M → 488.64M (in $), with an average decrease of 1.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -36.95M → 7.28M (in $), with an average increase of 607.5% per quarter

  • Vs CL

    In the last 1 year, Colgate-palmolive Co. has given 14.8% return, outperforming this stock by 84.6%

  • Vs PG

    In the last 3 years, Procter & Gamble Company, The has given 7.5% return, outperforming this stock by 84.2%

Performance

  • $12.36
    $12.82
    $12.70
    downward going graph

    2.68%

    Downside

    Day's Volatility :3.59%

    Upside

    0.94%

    downward going graph
  • $11.84
    $39.25
    $12.70
    downward going graph

    6.77%

    Downside

    52 Weeks Volatility :69.83%

    Upside

    67.64%

    downward going graph

Returns

PeriodNu Skin Enterprises Inc.Sector (Consumer Staples)Index (Russel 2000)
3 Months
-28.84%
1.5%
0.0%
6 Months
-36.97%
7.9%
0.0%
1 Year
-69.79%
-3.3%
-1.5%
3 Years
-76.93%
5.1%
-21.8%

Highlights

Market Capitalization
609.9M
Book Value
$16.61
Dividend Share
1.56
Dividend Yield
1.95%
Earnings Per Share (EPS)
0.17
PE Ratio
72.24
PEG Ratio
2.35
Wall Street Target Price
15.5
Profit Margin
0.44%
Operating Margin TTM
18.78%
Return On Assets TTM
4.61%
Return On Equity TTM
1.0%
Revenue TTM
2.0B
Revenue Per Share TTM
39.61
Quarterly Revenue Growth YOY
-6.5%
Gross Profit TTM
1.6B
EBITDA
203.0M
Diluted Eps TTM
0.17
Quarterly Earnings Growth YOY
-0.88
EPS Estimate Current Year
1.14
EPS Estimate Next Year
1.55
EPS Estimate Current Quarter
0.28
EPS Estimate Next Quarter
0.34

Analyst Recommendation

Hold
    0
    0%Buy
    54%Hold
    45%Sell
Based on 11 Wall street analysts offering stock ratings for Nu Skin Enterprises Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
6
6
6
Sell
5
5
5

Analyst Forecast

What analysts predicted

Upside of 22.05%

Current $12.70
Target $15.50

Company Financials

FY18Y/Y Change
Revenue
2.7B
↑ 17.55%
Net Income
121.9M
↓ 5.83%
Net Profit Margin
4.55%
↓ 1.13%
FY19Y/Y Change
Revenue
2.4B
↓ 9.65%
Net Income
173.6M
↑ 42.39%
Net Profit Margin
7.17%
↑ 2.62%
FY20Y/Y Change
Revenue
2.6B
↑ 6.67%
Net Income
191.4M
↑ 10.26%
Net Profit Margin
7.41%
↑ 0.24%
FY21Y/Y Change
Revenue
2.7B
↑ 4.41%
Net Income
147.3M
↓ 23.04%
Net Profit Margin
5.46%
↓ 1.95%
FY22Y/Y Change
Revenue
2.2B
↓ 17.44%
Net Income
104.8M
↓ 28.85%
Net Profit Margin
4.71%
↓ 0.75%
FY23Y/Y Change
Revenue
2.0B
↓ 11.53%
Net Income
8.6M
↓ 91.8%
Net Profit Margin
0.44%
↓ 4.27%
Q3 FY22Q/Q Change
Revenue
537.8M
↓ 4.07%
Net Income
-25.4M
↓ 174.16%
Net Profit Margin
-4.72%
↓ 10.83%
Q4 FY22Q/Q Change
Revenue
522.3M
↓ 2.88%
Net Income
57.2M
↓ 325.34%
Net Profit Margin
10.95%
↑ 15.67%
Q1 FY23Q/Q Change
Revenue
481.5M
↓ 7.83%
Net Income
11.4M
↓ 80.12%
Net Profit Margin
2.36%
↓ 8.59%
Q2 FY23Q/Q Change
Revenue
500.3M
↑ 3.9%
Net Income
26.9M
↑ 136.39%
Net Profit Margin
5.38%
↑ 3.02%
Q3 FY23Q/Q Change
Revenue
498.8M
↓ 0.3%
Net Income
-37.0M
↓ 237.42%
Net Profit Margin
-7.41%
↓ 12.79%
Q4 FY23Q/Q Change
Revenue
488.6M
↓ 2.03%
Net Income
7.3M
↓ 119.71%
Net Profit Margin
1.49%
↑ 8.9%
FY18Y/Y Change
Total Assets
1.7B
↑ 6.58%
Total Liabilities
912.6M
↑ 3.08%
FY19Y/Y Change
Total Assets
1.8B
↑ 4.4%
Total Liabilities
893.7M
↓ 2.07%
FY20Y/Y Change
Total Assets
2.0B
↑ 10.63%
Total Liabilities
1.1B
↑ 18.92%
FY21Y/Y Change
Total Assets
1.9B
↓ 2.59%
Total Liabilities
993.7M
↓ 6.5%
FY22Y/Y Change
Total Assets
1.8B
↓ 4.49%
Total Liabilities
923.7M
↓ 7.05%
FY23Y/Y Change
Total Assets
1.8B
↓ 0.8%
Total Liabilities
984.5M
↑ 6.58%
Q3 FY22Q/Q Change
Total Assets
1.8B
↓ 7.25%
Total Liabilities
921.2M
↓ 4.02%
Q4 FY22Q/Q Change
Total Assets
1.8B
↑ 3.28%
Total Liabilities
923.7M
↑ 0.26%
Q1 FY23Q/Q Change
Total Assets
1.8B
↑ 0.2%
Total Liabilities
931.7M
↑ 0.87%
Q2 FY23Q/Q Change
Total Assets
1.9B
↑ 3.79%
Total Liabilities
998.4M
↑ 7.17%
Q3 FY23Q/Q Change
Total Assets
1.8B
↓ 5.32%
Total Liabilities
970.9M
↓ 2.76%
Q4 FY23Q/Q Change
Total Assets
1.8B
↑ 0.75%
Total Liabilities
984.5M
↑ 1.4%
FY18Y/Y Change
Operating Cash Flow
202.7M
↓ 32.99%
Investing Cash Flow
-108.8M
↑ 18.26%
Financing Cash Flow
-116.7M
↓ 26.86%
FY19Y/Y Change
Operating Cash Flow
177.9M
↓ 12.24%
Investing Cash Flow
-71.4M
↓ 34.34%
Financing Cash Flow
-154.8M
↑ 32.63%
FY20Y/Y Change
Operating Cash Flow
379.1M
↑ 113.08%
Investing Cash Flow
-79.4M
↑ 11.23%
Financing Cash Flow
-245.2M
↑ 58.38%
FY21Y/Y Change
Operating Cash Flow
141.6M
↓ 62.66%
Investing Cash Flow
-88.7M
↑ 11.71%
Financing Cash Flow
-104.7M
↓ 57.29%
FY22Y/Y Change
Operating Cash Flow
108.1M
↓ 23.68%
Investing Cash Flow
-67.1M
↓ 24.4%
Financing Cash Flow
-99.5M
↓ 4.96%
Q3 FY22Q/Q Change
Operating Cash Flow
28.4M
↓ 38.91%
Investing Cash Flow
-25.2M
↑ 37.39%
Financing Cash Flow
-61.1M
↓ 232.39%
Q4 FY22Q/Q Change
Operating Cash Flow
25.5M
↓ 10.25%
Investing Cash Flow
-13.4M
↓ 46.91%
Financing Cash Flow
-50.8M
↓ 16.88%
Q1 FY23Q/Q Change
Operating Cash Flow
-22.1M
↓ 186.49%
Investing Cash Flow
-14.7M
↑ 9.79%
Financing Cash Flow
1.4M
↓ 102.72%
Q2 FY23Q/Q Change
Operating Cash Flow
35.5M
↓ 260.9%
Investing Cash Flow
-92.5M
↑ 529.43%
Financing Cash Flow
68.0M
↑ 4826.74%
Q3 FY23Q/Q Change
Operating Cash Flow
51.0M
↑ 43.65%
Investing Cash Flow
-11.9M
↓ 87.13%
Financing Cash Flow
-38.4M
↓ 156.44%

Technicals Summary

Sell

Neutral

Buy

Nu Skin Enterprises Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc.
-3.89%
-36.97%
-69.79%
-76.93%
-75.17%
Colgate-palmolive Co.
Colgate-palmolive Co.
-1.72%
18.72%
14.84%
7.94%
25.09%
Estée Lauder Companies Inc.
Estée Lauder Companies Inc.
-6.62%
-0.43%
-46.3%
-55.35%
-18.96%
Procter & Gamble Company, The
Procter & Gamble Company, The
-2.64%
4.62%
3.8%
14.9%
48.01%
Kenvue Inc.
Kenvue Inc.
-4.6%
-3.94%
-28.36%
-28.36%
-28.36%
Kimberly-clark Corp.
Kimberly-clark Corp.
1.39%
2.05%
-9.2%
-9.34%
1.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc.
72.24
72.24
2.35
1.14
0.01
0.05
0.02
16.61
Colgate-palmolive Co.
Colgate-palmolive Co.
31.11
31.11
2.15
3.49
2.79
0.15
0.02
0.74
Estée Lauder Companies Inc.
Estée Lauder Companies Inc.
106.15
106.15
1.6
2.25
0.07
0.03
0.02
15.94
Procter & Gamble Company, The
Procter & Gamble Company, The
26.12
26.12
3.28
6.45
0.32
0.11
0.03
20.28
Kenvue Inc.
Kenvue Inc.
21.34
21.34
2.11
1.14
0.11
0.07
0.04
5.85
Kimberly-clark Corp.
Kimberly-clark Corp.
24.05
24.05
1.57
6.9
2.0
0.1
0.04
2.72
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc.
Hold
$609.9M
-75.17%
72.24
0.44%
Colgate-palmolive Co.
Colgate-palmolive Co.
Buy
$70.8B
25.09%
31.11
11.82%
Estée Lauder Companies Inc.
Estée Lauder Companies Inc.
Buy
$49.2B
-18.96%
106.15
3.08%
Procter & Gamble Company, The
Procter & Gamble Company, The
Buy
$367.0B
48.01%
26.12
17.6%
Kenvue Inc.
Kenvue Inc.
Buy
$36.8B
-28.36%
21.34
10.77%
Kimberly-clark Corp.
Kimberly-clark Corp.
Hold
$42.2B
1.95%
24.05
8.63%

Institutional Holdings

  • BlackRock Inc

    17.22%

  • Vanguard Group Inc

    12.58%

  • State Street Corporation

    5.81%

  • Amvescap Plc.

    5.78%

  • Renaissance Technologies Corp

    3.90%

  • Dimensional Fund Advisors, Inc.

    2.82%

Corporate Announcements

  • Nu Skin Enterprises Inc. Dividends March,2024

    In the quarter ending March,2024. Nu Skin Enterprises Inc. has declared dividend of $0.06

    Read More

Company Information

founded 35 years ago, nu skin enterprises, inc. (nse) empowers innovative companies to change the world with sustainable solutions, opportunities, technologies, and life-improving values. the company currently focuses its efforts around innovative consumer products, product manufacturing and automated controlled environment agriculture technology. the nse family of companies includes: nu skin, groviv, wasatch labs, elevate health sciences, and casepak. nu skin enterprises is traded on the new york stock exchange under the symbol "nus." more information is available at nuskinenterprises.com.

Organization
Nu Skin Enterprises Inc.
Employees
3700
CEO
Mr. Steven J. Lund
Industry
All Other Miscellaneous Chemical Product and Preparation Manufacturing

Discover More

FAQs